• How Portage Biotech Created A Lean, New Drug Development Model

    Dr. Ian Walters noticed that Big Pharma companies often would lament that small biotechs did not develop drugs the same way as their larger counterparts. He set out to change that.

  • How A Robust R&D Pipeline Can Safeguard Innovation

    By approaching R&D only as a means to a profitable product and not as a valuable asset for the broader scientific or consumer community, companies and the industry lose out on opportunities for innovation, collaboration, and discovery.

  • Fueling A Focused Drug Development Model

    Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end, and commercialization on the other.

  • What’s True Of Mice ≠ What’s True Of Men

    As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological research and testing. LIfT Biosciences’ Founder and CEO Alex Blyth is a vocal proponent of organoid/tumoroid models.

  • Is AI/ML Bringing Medicines To Patients Faster And Cheaper?

    It is critical to move beyond simply using AI as a buzzword and instead determine if AL/ML does indeed change the discovery and clinical development process by bringing innovation to patients faster and at a lower investment.

  • Building A Successful Internal Innovation Incubator

    With so many internal incubators failing, what is the right formula for success? Leading the U.S. Digital Transformation & Innovation team for Novo Nordisk, I was on the frontlines addressing this very question.

  • Platforms To Pipelines: Part 1

    To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.

  • IP Do’s And Don’ts For Early-Stage Life Sciences Companies

    Early-stage life sciences companies typically focus their time and resources on developing their core products, positioning them for commercial success, and, if applicable, obtaining FDA approval. Intellectual property protection is often further down their list of priorities. This is a mistake.

  • Tackling Uncertainty In Drug R&D

    Can bioinformatics help biopharma companies manage their expectations and limit their risk in drug R&D? Ben Zeskind, a CEO who has built and bet his entire career on a positive answer to that question, discusses his reasons for optimism.

  • COVID Presents An Opportunity For Rural Biopharma Innovation

    During the COVID pandemic, skilled workers began leaving urban centers (or the workforce altogether) to improve their quality of life and get some literal and figurative distance. How do we ensure that innovation follows?